Acacia's Euronext Listing To Help Target Unmet US PONV Market

Acacia Pharma’s long-term aim, once its go-it-alone US strategy is in hand, is to turn its attention to ex-US partnering possibilities for its lead product for post-operative nausea and vomiting. It will also develop a Phase II candidate for chemotherapy-induced nausea and vomiting.